Clinical Trial Update: Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial results for mesenchymal stromal cell therapy in SARS-CoV-2–induced acute respiratory failure (COVID-19) with results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Drugs mentioned

• Mesenchymal stromal cells

Snippet

Sponsor: Baylor College of Medicine | Conditions: Sars-CoV2, Acute Respiratory Distress Syndrome | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-04-01